Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for antipsychotic-induced weight gain in schizophrenia (RCT)
ChiCTR2400089293Phase 2Completed
- Sponsor
- Tai Po Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Schizophrenia Spectrum and Other Psychotic Disorders (SZ) and cardiometabolic risk (CMR) comparing Empagliflozin + lifestyle intervention with Placebo + lifestyle intervention (2 arms). Primary endpoints: Body weight and Body mass index (BMI). Started Sep 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR2400089293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089293.